DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024

Then, on May 8, 2024, before the market opened, the Company filed with the SEC a current report on Form 8- K. Attached to this Form 8-K was a press release in which the Company announced that it would stop clinical trial enrollment in the RAISE and RAISE II trials. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequa ...